ANDOVER, Mass.–(BUSINESS WIRE)–Vastrax, a premier full-service Contract Research Organization (CRO) with a mission to expedite the development of cutting-edge technologies in the vascular market, proudly announces the appointment of Aimee DeGaetano as the Global Head of Commercial and Clinical Affairs. “Our dedication to accelerating advancements in the vascular sector is […]
Other News
ACTIMIS Post-hoc Results on Imaging Stroke Data Using Artificial Intelligence Reinforces Glenzocimab Mode of Action in Stroke Patients
PARIS–(BUSINESS WIRE)–Acticor Biotech, (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announced today the results of its collaboration with Brainomix Limited, to further explore the imaging data using Artificial Intelligence (AI) from its phase 1b/2a ACTIMIS study. The ACTIMIS […]
AI Therapeutics Announces Initiation of a Phase 2 Clinical Trial of LAM-001 for Treatment of Pulmonary Arterial Hypertension (PAH)
GUILFORD, Conn., Aug. 31, 2023 (GLOBE NEWSWIRE) — AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the initiation of a Phase 2 study for its novel inhaled form of sirolimus, LAM-001, for the treatment of pulmonary arterial hypertension (PAH). PAH is a rapidly progressive […]
HeartSciences Signs Distribution Agreement with FJ Medical, Denmark
Southlake, TX, Aug. 31, 2023 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has signed a distribution agreement with FJ […]
RhythmScience Announces Formation of Medical Advisory Board
SAN FRANCISCO, Aug. 31, 2023 /PRNewswire/ — RhythmScience, a leader in cardiac data management and services, today announced the formation of its Medical Advisory Board (MAB). Comprised of renowned experts across heart failure and rhythm management, the MAB will provide invaluable clinical guidance and strategic insights to further advance RhythmScience’s mission of […]
Zylox-Tonbridge’s ZENFlow Tiger™ LD PTA Dilatation Catheter Receives ANVISA Marketing Approval
HANGZHOU, China, Aug. 30, 2023 /PRNewswire/ — Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK, hereinafter referred to as “Zylox-Tonbridge” or the “Company”) announced that its ZENFlow Tiger™ LD PTA Dilatation Catheter (hereinafter referred to as “ZENFlow Tiger™”), a product independently developed by the Company, has received marketing approval from ANVISA. The Company expects […]
Aziyo Biologics Announces Publication of a CanGaroo® Case Study Demonstrating Bioenvelope Benefits for Reoperative Procedures
SILVER SPRING, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced the publication of a case report highlighting results that demonstrate the potential benefits […]
LifeTech Scientific Corporation (1302.HK) Announces 2023 Interim Results
SHENZHEN, China , Aug. 30, 2023 /PRNewswire/ — LifeTech Scientific Corporation (the “Company” or “Lifetech”), a leading company specialized in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, today announced the unaudited consolidated results of the Company and its subsidiaries (collectively the “Group”) for the six months ended 30 June 2023 (the “Reporting […]
European Society of Cardiology Congress: Traditional Chinese Medicine Qili Qiangxin significantly reduces the risk of cardiovascular death and re-hospitalization due to heart failure
AMSTERDAM, Aug. 30, 2023 /PRNewswire/ — The latest study indicates that adding TCM Qili Qiangxin Capsules (developed and produced by Yiling Pharmaceutical) to the standard of care for heart failure can significantly reduce the risk of re-hospitalization due to worsening heart failure and cardiovascular death in patients with chronic heart failure. On August […]
Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)
NEW YORK, Aug. 30, 2023 /PRNewswire/ — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, today announced the expanded evaluation of tecarfarin for the treatment […]



